SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Zora Neale Hurston — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientZora Neale Hurston
Date of birth1891-01-07
IdentifiersMRN HR-ML040-SYN-TD; SSN (made up) 000-40-6213
Document date1958-06-01
AuthorLorraine Abernathy-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eight-week review: blood pressure, potassium, lipids and heart failure. [S]

History of Present Illness

Ms. Hurston returns eight weeks after spironolactone was added and two weeks after her sick visit for lightheadedness in the heat. She restarted chlorthalidone, spironolactone and dapagliflozin after two days, as planned; the lightheadedness has not returned since she moved her gardening to the early morning and drinks water through the day, and the energy assistance application for cooling help is in. She did not have the metabolic panel one to two weeks after starting spironolactone: the bus route to the laboratory changed, and she had no ride. Her home blood pressure average this week is 124/74, and she has no breathlessness on the stairs at school. Extra Help and the Medicare Savings Program were approved, and the SHINE counselor helped her choose a drug plan that begins next month. [S]

ElementDetail
Home blood pressureAverage 124/74 mmHg
Missed testMetabolic panel one to two weeks after spironolactone not done; no ride to the laboratory
Since the sick visitMedicines restarted after two days; no further lightheadedness
CoverageExtra Help and Medicare Savings Program approved; drug plan begins next month
KCCQ-1272, from 54

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest pain, palpitations or edema; breathless only on hurrying uphill
NeurologicalNegativeNo lightheadedness, headache, weakness or speech change
MusculoskeletalNegativeNo muscle aches on atorvastatin
BreastNegativeNo breast tenderness or swelling on spironolactone

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet every morningOne tablet every morningOral route1958-03-09activeS
Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morningOne-half tablet every morningOral route1958-03-09activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route1958-03-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1958-03-23activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) dailyOne-half tablet dailyOral route1958-04-06activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1958-06-01Body height165cmS
1958-06-01Body weight81.8kgS
1958-06-01Body mass index (BMI) [Ratio]30kg/m2S
1958-06-01Systolic blood pressure126mm[Hg]S
1958-06-01Diastolic blood pressure76mm[Hg]S
1958-06-01Heart rate72/minS
1958-06-01Respiratory rate16/minS
1958-06-01Body temperature36.6CelS
1958-06-01Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1958-06-01Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1958-06-01Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1958-06-01Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.59-1.04 mg/dLNormalS
1958-06-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1953)/1.73 sq M65mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1958-06-01Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
1958-06-01Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
1958-06-01Cholesterol [Mass/volume] in Serum or Plasma152mg/dL<=199 mg/dLNormalS
1958-06-01Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation76mg/dL<=99 mg/dLNormalS
1958-06-01Cholesterol in HDL [Mass/volume] in Serum or Plasma53mg/dL>=50 mg/dLNormalS
1958-06-01Triglyceride [Mass/volume] in Serum or Plasma115mg/dL<=149 mg/dLNormalS
1958-06-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
1958-06-01Overall summary score [KCCQ-12]72{score}S

Physical Exam

Vital signs recorded on 1958-06-01; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/76, pulse 72; weight 81.8 kg
Orthostatic vital signsStanding at three minutes 122/74 mmHg without symptoms
NeckJugular venous pressure not raised
CardiovascularRegular rhythm; S4
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Very high blood pressure at intake (178/104 and 174/102 mmHg) with morning headaches for two months, without signs of a hypertensive emergency; not previously diagnosed; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting problem, resolved when ambulatory monitoring and the echocardiogram established the diagnosis at the second visit. Not a claim about her real blood pressure.
Breathlessness on exertion for three months (walking to the school, carrying groceries) with mild ankle swelling by evening; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved into the heart failure diagnosis at the second visit.
Hypertensive heart disease with heart failure: stage 2 hypertension confirmed by 24-hour ambulatory monitoring (mean 158/96 mmHg, non-dipping at night), with concentric left ventricular hypertrophy on ECG and echocardiogram; synthetic modern episode linked to the hypertensive heart disease recorded as her cause of deathactiveconfirmed I11.0S — Synthetic modern diagnosis made at the second visit; the 1960 cause of death remains D.
Heart failure with preserved ejection fraction (ejection fraction 62%), NYHA class II, with grade II diastolic dysfunction and an enlarged left atriumactiveconfirmed I50.32S — Synthetic modern diagnosis confirmed by echocardiogram and cardiology at the second visit.
Food insecurity: food runs short at the end of most months (Hunger Vital Sign positive)activeconfirmed Z59.41S — Synthetic social need anchored to her documented poverty.
Low and irregular income from substitute teaching and newspaper writing, with Original Medicare but no drug coverage; medicine costs a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented low income in the 1950s.
Orthostatic hypotension with lightheadedness on standing, from volume depletion in early summer heat on a diuretic, spironolactone and an SGLT2 inhibitor; no fall or faint; resolved after two days off those medicines and more fluidresolvedconfirmed I95.1S — Synthetic intercurrent problem at an unscheduled visit; it follows from the treatment plan and the climate and does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure in the clinic (seated, average of two readings, large cuff)Every visitCompleted today126/76 mmHg; no orthostatic drop
ExaminationOut-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes)At diagnosis and with each treatment changeCompleted todayHome average 124/74 mmHg
ExaminationWeight, volume status (jugular venous pressure, edema, lungs) and NYHA classEvery visitCompleted today81.8 kg; jugular venous pressure not raised; no edema; NYHA I to II
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six monthsDeferredThe panel due one to two weeks after spironolactone was started was missed: the bus route to the laboratory changed and she had no ride. The first check came at the sick visit six weeks after the start: potassium 4.4 mmol/L, with creatinine 1.10 mg/dL from volume depletion in the heat, not from the potassium. No harm from the missed check is evident: no hyperkalemia at six weeks or today. Corrective action: laboratory tests on clinic visit days where possible, and rides through the county's transportation program for any separate trip
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six monthsCompleted todaySodium 138, potassium 4.2, creatinine 0.96 mg/dL (eGFR 65), magnesium 2.0
LaboratoryLipid panelFour to twelve weeks after starting a statin; then yearlyCompleted todayTen weeks on atorvastatin: LDL 76 mg/dL, total cholesterol 152, HDL 53, triglycerides 115; ALT 19 U/L
SurveyKCCQ-12 heart failure health statusAt diagnosis, then every three to six monthsCompleted today72, from 54 at diagnosis
ImagingECG and echocardiogramAt diagnosis; repeat only with unexplained clinical changeNot indicatedImproving; no unexplained change
Medication safetySGLT2 inhibitor and MRA: volume depletion, potassium and sick-day rulesEvery visitCompleted todayOrthostatic episode in the heat managed by the sick-day rules; no recurrence; potassium in range
Self-managementSelf-care: daily weights, less salt, sick-day rules and the BE FAST stroke signsEvery visitCompleted todayDaily weights; heat plan; BE FAST reviewed
Medication safetyMedicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program)Every visitCompleted todayExtra Help and Medicare Savings Program approved; drug plan begins next month
Self-managementFood accessEvery visitCompleted todayFood lasts the month with SNAP and the pantry

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026); Signs and Symptoms of Stroke (2026); Help with drug costs (Extra Help) (2026); Medicare Savings Programs (2026); Low Income Home Energy Assistance Program (LIHEAP) (2026)

Follow-up: Annual wellness visit in about three months. Heart failure and blood pressure review in about four months with a metabolic panel and the KCCQ-12. Call for lightheadedness or a weight change beyond the plan; call 911 for any BE FAST sign. Next scheduled visit 1958-09-14: subsequent annual wellness visit. [S]